New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2013
06:06 EDTAGNAllergan has 'sleeper hit' with Ozurdex, says BMO Capital
BMO Capital believes Allergan's biodegradable intravitreal implant for the treatment of diabetic macular edema, Ozurdex, will be approved in mid-2014 and be a "sleeper hit" for the company. BMO thinks Ozurdex, which is currently approved for macular edema related to retinal vein occlusion, can be a $200M-$300M product by 2020 in the U.S. alone. The firm raised its price target for Allergan shares to $117 from $112 and keeps an Outperform rating on the stock.
News For AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent AGN news | >>
November 17, 2014
09:10 EDTAGNActavis buying Allergan for $219 per share, CNBC reports
06:05 EDTAGNActavis close to buying Allergan for over $64B, Bloomberg reports
Subscribe for More Information
November 16, 2014
14:02 EDTAGNAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information
November 13, 2014
07:23 EDTAGNValeant wooing doctors ahead of hoped for Allergan acquisition, WSJ says
Subscribe for More Information
November 12, 2014
16:53 EDTAGNAllergan receives FDA approval for new styles of NATRELLE 410
Subscribe for More Information
10:09 EDTAGNActavis in talks to buy Allergan for over $200 per share, Bloomberg says
Subscribe for More Information
10:01 EDTAGNActavis in talks to buy Allergan for $60B, more than $200/share Bloomberg says
Actavis (ACT) is said to seek to pay about $200 per share, but Allergan (AGN) seeks about $210 per share, according to Bloomberg.
07:01 EDTAGNAllergan announces approval of amendments to company bylaws
Subscribe for More Information
06:22 EDTAGNZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 11, 2014
15:46 EDTAGNPershing Square, Sachem Head build 10% stake in Zoetis, WSJ reports
Subscribe for More Information
08:32 EDTAGNValeant likely to raise offer for Allergan again, says Bernstein
Subscribe for More Information
November 9, 2014
13:26 EDTAGNAckman's Allergan court win may prove costly down the road, Bloomberg says
When U.S. District Court Judge David Carter ruled on November 4 that Pershing Square can vote its 9.7% stake in Allergan (AGN) in a shareholder ballot aiming to remove Allergan directors, he also noted that there were “serious questions” regarding insider trading rules in the way Pershing Square acquired Allergan stock while preparing a bid with Valeant (VRX), says Bloomberg. Reference Link
November 7, 2014
14:56 EDTAGNAllergan says Valeant offers to date inadequate, would consider increased bid
Subscribe for More Information
09:49 EDTAGNAckman says Allergan 'tipping scales' in Actavis’ favor, disadvantaging Valeant
Subscribe for More Information
November 6, 2014
10:30 EDTAGNAllergan disclosure today forced by SEC, CNBC's Faber reports
Subscribe for More Information
10:05 EDTAGNActavis talks to buy Salix put on hold, Bloomberg says
Subscribe for More Information
09:28 EDTAGNActavis in active talks to acquire Allergan, Bloomberg reports
Actavis (ACT) is in active talks to acquire Allergan (AGN), Bloomberg reports, citing sources. Allergan earlier today disclosed in a filing that it has been approached by another party and that talks "may lead to negotiations." Shares of Allergan are up 1.1% to $198.50 in pre-open trading while Actavis is up 1% to $250.07. Valeant (VRX) is down 1.8% to $129.58. Reference Link
09:24 EDTAGNActavis in active talks to acquire Allergan, Bloomberg reports
Subscribe for More Information
09:11 EDTAGNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Tesla (TSLA), up 0.6%... CBS (CBS), up 2.3%... Whole Foods (WFM) up 8.4%... American Capital (ACAS), up 9.5%... Horizon Pharma (HZNP) up 6.8%... Kate Spade (KATE), up 10%. ALSO HIGHER: Planar Systems (PLNR), up 70%, upgraded at Needham following the company's Q4 results... Tableau (DATA), up 9.8%, upgraded at RBC Capital following the company's Q3 earnings report... Allergan (AGN), up 1% after disclosing in new regulatory filing that discussions between the company and another unnamed party regarding a potential merger transaction have continued and "may lead to negotiations.” DOWN AFTER EARNINGS: Qualcomm (QCOM), down 6.9%... Zillow (Z), down 6.7%... PhotoMedex (PHMD), down 17.3%... Kulicke & Soffa (KLIC), down 7%... BioScrip (BIOS), down 5.8%. ALSO LOWER: Solazyme (SZYM), down 47%, downgraded at RW Baird, Pacific Crest and Cowen following the company's Q3 report... Genworth (GNW), down 23%, downgraded at Compass Point following the company's Q3 results... Cornerstone OnDemand (CSOD), down 19%, downgraded at various firms including William Blair and FBR Capital following the company's Q3 report.
09:06 EDTAGNAllergan says approach may lead to merger negotiations
Allergan (AGN) disclosed in new regulatory filing, “Notwithstanding the foregoing, we have been approached by another party regarding a potential merger transaction. Discussions between us and that party have continued and may lead to negotiations.” It has been reported that the unnamed party is Actavis (ACT). Allergan is attempting to fend off a hostile takeover by Valeant (VRX).
1 | 2 | 3 | all recent AGN news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use